Ab­b­Vie’s im­munol­o­gy block­busters make up for Hu­mi­ra sales drop in Q3

Ab­b­Vie is lift­ing its prof­it out­look and full-year 2024 guid­ance as its im­munol­o­gy block­busters Skyrizi and Rin­voq beat quar­ter­ly rev­enue es­ti­mates, ac­cord­ing to the com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER